Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200221_IR_Chugai_eRozlytrek_ROS1-NSCLC_Approval.pdf Do not hesitate to contact us for any further questions. With best regards,
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news